Navigation Links
Nitto Denko Avecia Inc. Strengthens its Commitment to the Small Molecule and Radiochemistry Industries by Hiring Hamilton J. Lenox as Director of Business Development
Date:12/19/2013

(PRWEB) December 19, 2013

Nitto Denko Avecia Inc., an industry leader in process development and commercial manufacturing, is proud to announce that it has hired Hamilton J. Lenox as its new Director of Business Development. Hamilton initially will focus on the small molecule and radiochemistry units of Avecia, and also will be handling marketing for the organization. Hamilton brings both a strong technical background and significant business development expertise to Avecia, including familiarity both with clients and the outsourcing markets in North America, Europe and Asia.

The hiring of Hamilton, who is well known in the small molecule industry, demonstrates Avecia’s continuing commitment to their small molecule and radiochemistry customers. Early in 2013 Avecia acquired the contract manufacturing business of Girindus America Inc., adding small molecule API manufacturing and radiochemistry capabilities while expanding Avecia’s best in class oligonucleotide offerings.

Hamilton says he is excited to join Nitto Denko Avecia, Inc., a company well-known for their excellent reputation and strong leadership. “I look forward to expanding our client base in my new role, and know our existing and future clients will continue to be impressed with Avecia’s commitment to quality in everything we do,” says Hamilton. He notes that the acquisition of Girindus America’s contract manufacturing business not only keeps Avecia positioned as the leader of the oligonucleotide manufacturing market, but also significantly expands their capabilities.

Additionally, small molecule services have complemented Avecia’s oligonucleotide business due to both units’ expertise in difficult conjugation chemistry, and Avecia now can produce any necessary small molecule linkers / conjugates in-house. The expertise of Avecia’s oligo team also has benefited the small molecule unit by providing additional expertise that clearly positions Avecia as a leader in developing and manufacturing small molecule nucleotide derivatives and analogs. There also is a strong synergy between the oligo and radiochemistry units, as this combination marks Avecia as one of the only radiochemistry facilities in the world with significant expertise in oligo synthesis.

About Nitto Denko Avecia, Inc.:
Nitto Denko Avecia, Inc., is a drug development and manufacturing services company with headquarters in Milford, MA, and is a part of Nitto Denko Corporation, Japan’s leading diversified materials manufacturer. Avecia is a recognized leader in the oligonucleotide therapeutic market, and with the acquisition of Girindus America’s contract manufacturing business in 2013 has added radiochemistry and small molecule API development and manufacturing to its portfolio of services. Avecia’s oligonucleotide facilities (in Milford, MA, and Cincinnati, OH) support DNA and RNA-based therapeutics throughout their lifecycle, and include such services as process and analytical development and pre-clinical production through large scale cGMP commercial manufacturing. To see what Avecia can do for your business, visit http://www.avecia.com.

Read the full story at http://www.prweb.com/releases/2013/12/prweb11430949.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. NITTO DENKO Avecia Inc. Introduces Dedicated Pre-Clinical Oligonucleotide Service, OliGrow
2. Intrexon Strengthens Leadership in Companys Rapidly Growing Health Sector
3. Gallus Strengthens Biologics CMO Business with Acquisition of Laureate
4. inVentiv Health Clinical Expands and Strengthens Executive Team with Three Strategic Appointments
5. SentoClone International AB Significantly Strengthens its Global Patent Portfolio Covering its Clinical Stage Sentinel Node-derived CD4 T-cell Cancer Therapy
6. BellBrook Labs Strengthens Ties with Cambio for Distribution of Transcreener HTS Assays in the UK
7. Cytos Biotechnology Strengthens Management Team
8. Delta Point Strengthens Management and Expands Consultancy Services with Addition of Former AstraZeneca Executive Michael Hickey
9. Molecular Detection Inc. Further Strengthens Patent Portfolio Broadly Covering Detection of Antibiotic-Resistant Bacteria
10. AMRI Strengthens Business Development and Marketing Groups
11. Hospira Names Zena G. Kaufman Senior Vice President of Quality; Strengthens Quality and Compliance Capabilities With Addition of Top Industry Talent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... KNOXVILLE, Tenn. , Feb. 24, 2017 /PRNewswire/ ... ) ("Provectus" or the "Company"), a clinical-stage oncology ... information regarding the deadline to participate in its ... million units, consisting of shares of common stock ... stockholders and holders of listed warrants. ...
(Date:2/24/2017)... Symic Bio, a biopharmaceutical company focused on ... therapeutics, announced today the completion of enrollment for the ... The trial will evaluate the safety and efficacy of ... of restenosis following angioplasty. "We,re pleased ... said Nathan Bachtell , M.D., Chief Medical Officer ...
(Date:2/24/2017)... China Cord Blood Corporation (NYSE: CO ) ... blood collection, laboratory testing, hematopoietic stem cell processing and ... results for the third quarter and first nine months ... Third Quarter of Fiscal 2017 Highlights ... increased by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), ... announced its financial results for the fourth quarter and fiscal ... Highlights Total sales in the fourth ... increased by 13.6% in USD terms to $77.6 million from ... Gross profit increased by 13.3% to $46.8 million from ...
Breaking Biology Technology:
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
(Date:1/31/2017)... 31, 2017  Spero Therapeutics, LLC, a biopharmaceutical ... treatment of bacterial infections, today announced it has ... from Pro Bono Bio Ltd (PBB) to bolster ... resistant forms of Gram-negative bacteria.   The assets acquired ... a PBB group company. "The acquisition ...
(Date:1/25/2017)... , Jan. 25, 2017 The Elements of ... (IAM) lifecycle is comprised of a comprehensive set ... purpose of maintaining digital identities and providing a ... applications. There are significant number of programs opted ... to time by optimizing processes and changing policies. ...
Breaking Biology News(10 mins):